The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2021 | Myeloma: where is I-O moving?
Parameswaran Hari
• 7 May 2021
Immuno-Oncology (I-O) has rapidly advanced the myeloma field, with bispecific antibodies and immune effector cells (such as CAR-T cells and NK cells) being the two major forms of I-O. Parameswaran Hari, MBBS, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the immuno-oncology space, and where he believes the field will move. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.
